Dientamoeba fragilis: clinical symptoms, optimal treatment and molecular detection

Dientamoeba fragilis: clinical symptoms, optimal treatment and molecular detection - Dientamoeba fragilis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON39247

Enrollment

500

Registered

2010-06-21

Start date

2010-10-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

'Dientamoeba fragilis infection'

Interventions

After informed consent from parents and/or patient, participants will be treated with Clioquinol 15 mg/kg/day in 3dd for 10 days or metronidazol 30 mg/kg/day in 3dd for 10 days.

Eligibility

Age

2 Years to 17 Years

Inclusion criteria

Inclusion criteria: - Subjects in between 0 and 18 years of age - Positive PCR for Dientamoeba fragilis

Exclusion criteria

Exclusion criteria: - Contra-indication for the use of Metronidazole or Clioquinol - Pregnancy - Underlying disease or use of medication

Design outcomes

Primary

Measure	Time frame
To determine differences in efficacy of anti-protozoal treatment with clioquinol or metronidazole in children with symptomatic Dientamoeba fragilis infection.	—

Secondary

Measure	Time frame
- To determine symptoms of Dientamoeba fragilis infection in children and adults - To assess duration of positivity of PCR after treatment - To determine incidence in non-symptomatic patients	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)